Sanofi-Aventis US (Sanofi-Aventis) has appointed Paul Chew as chief science officer (CSO)/chief medical officer (CMO), US, effective April 1, 2009. He was previously president, research & development (R&D), sanofi-aventis, US. As the company's CSO and CMO, Paul Chew will establish a unified medical voice for sanofi-aventis US among internal and external stakeholders.
Paul Chew will be responsible for overseeing US Medical Affairs in addition to his continued oversight of the US R&D organization in coordination with the Group in Paris. Further, Paul Chew will be charged with representing accurate and timely clinical and safety information to health authorities, payers, patients and physicians that will foster safe and appropriate use of our products.
Paul Chew’s primary reporting will be to Greg Irace, president and chief executive officer, sanofi-aventis US, in addition to Marc Cluzel, group senior vice president of R&D and Jean-Pierre Lehner, group chief medical officer.
“Paul brings deep, scientific expertise and proven leadership to both the R&D and Medical functions in the U.S. – a critical area in which the science and the business of our industry intersect,” said Greg Irace. “In this new role, Paul will be in a position to bring greater scientific and product insights to our organization, greater clarity and dialogue with members of the healthcare system and, ultimately, greater value to patients in the form of improved health outcomes.”
The new role of CSO and CMO is part of the company’s overall organizational drive to ensure all components of the US affiliate work in a coordinated manner to achieve harmonized processes, cost-effectiveness and best practice sharing in the design, conduct and monitoring of clinical studies.